In particular, neutrophils from FHL-5 patients, as well as neutrophils from patients with CGD, showed unexpectedly intact killing of HER2/neu+ breast cancer cells in the presence of the therapeutic antibody trastuzumab (149). Here, ERBB2 is linked to breast cancer.